Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 4,118 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia
Interventions: Bempedoic acid + Ezetimibe FDC Oral Tablet, Ezetimibe 10 mg Oral Tablet, Placebo Oral Tablet, Placebo oral capsule; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Lincoln, California • Miami, Florida • Louisville, Kentucky + 1 more

Conditions: Advanced Solid Tumors, Hematologic Malignancies
Interventions: IXAZOMIB; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Fairway, Kansas • Cleveland, Ohio • Dallas, Texas + 1 more

Conditions: Dyspepsia, Dietary Modification
Interventions: Low FODMAP Diet, Choose My Plate Diet; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Park Ridge, Illinois

Conditions: Solid Tumors
Interventions: ME-344; Drug
Lead sponsor: MEI Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee

Conditions: Central Nervous System Diseases, Pediatric Disorder, Body Indication
Interventions: Gadopiclenol; Drug
Lead sponsor: Guerbet; Industry
Eligibility: Up to 23 Months
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Cincinnati, Ohio • Charleston, South Carolina

Conditions: Stroke, Walking, Difficulty, Cardiovascular Injury
Interventions: Gait Training, Leg Cycling Exercise; Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Hematologic Malignancy, Leukemia, Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Non-Hodgkin
Interventions: CAR-37 T cells; Biological
Lead sponsor: Marcela V. Maus, M.D.,Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anemia, Sickle Cell, Hemoglobin SC Disease
Interventions: PAINReportIt (Phase 1 + 2), PAINUCope (Phase 1), PAINConsultN (Phase 2), PAINUCope (Phase 2); Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Systemic Lupus Erythematosus, Healthy Participants
Interventions: BMS-986165, Moxifloxacin, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Bipolar I
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 748 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 72
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 62 more

Conditions: Parkinson Disease
Interventions: transcranial direct current stimulation, Sham (for transcranial direct current stimulation); Device
Lead sponsor: Sanford Health; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Tinnitus, Noise Induced
Interventions: Etanercept, Saline; Biological · Other
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Celebration, Florida • Coral Gables, Florida • Detroit, Michigan + 1 more

Conditions: Healthy, Opioid Use Disorder
Interventions: Carfentanil, C-11, Naloxone, Loperamide Hydrochloride; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
Interventions: LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 25
States / cities: Duarte, California • Santa Monica, California • Denver, Colorado + 18 more

Conditions: COPD, Asthma, Cystic Fibrosis, Emphysema, Small Airways Disease
Interventions: Medical Grade Oxygen; Drug
Lead sponsor: Hal C Charles; Other
Eligibility: 18 Years to 90 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Depression
Interventions: leucine, PO placebo, lipopolysaccharide (LPS), IV placebo; Dietary Supplement · Other · Biological
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Opioid Use Disorder
Interventions: ERPs with electroencephalography (EEG), MIO; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Gaucher Disease, Type 1
Interventions: Eliglustat tartrate, Imiglucerase; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 17
States / cities: Beverly Hills, California • San Francisco, California • Aurora, Colorado + 13 more

Conditions: Inflammation, C-reactive Protein, Exercise Capacity
Interventions: Active Fruit Juice Intervention, Control Fruit Juice Intervention; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Thalamus
Interventions: LIFUP excitation, LIFUP inhibition; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 40 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Improving Treatment for Opioid Use Disorder in Courts
Interventions: eLearning Modules, Change Team Intervention; Behavioral
Lead sponsor: National Development and Research Institutes, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Hematologic Diseases
Interventions: Allogeneic Stem Cell Transplant, CliniMACS TCR α/β Reagent Kit and CliniMACS CD19; Biological · Device
Lead sponsor: Alice Bertaina; Other
Eligibility: 1 Month to 60 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Type 1 Diabetes
Interventions: Normal Glycemia Goal, Tight Glycemia Goal; Device
Lead sponsor: Mark D. DeBoer, MD, MSc., MCR; Other
Eligibility: 6 Years to 13 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: San Francisco, California • Aurora, Colorado • Charlottesville, Virginia

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir, Prednisone; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Buffalo, New York

Search by objective public record fields.

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction

Study to Evaluate Dietary Modification in Patients With Functional Dyspepsia.

Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors

Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age

To Develop a Walking Exercise Program for Non-ambulatory Stroke Survivors

CAR-37 T Cells in Hematologic Malignancies

Effectiveness of a Computerized Tool (PAINRelieveIt) to Help Manage Pain Related to Sickle Cell Disease

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

Transcranial Direct Current Stimulation for Cognitive Improvement in Parkinson's Patients

TNF-α Treatment of Blast-Induced Tinnitus

Multi-System Analysis of Opioid Receptor Binding

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Imaging Lung Function Using Oxygen Enhanced MRI

Leucine for Depression Study (L-DEP)

Neuroplasticity in Maternal Opioid Use Disorder (OUD)

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

What is the Effect of Increased Consumption of Fruit Juice on Exercise Capacity and Inflammatory Biomarkers?

Neuromodulation of Conscious Perception: Investigating Thalamic Roles Through Ultrasonic Stimulation

Facilitating MAT Acceptance & Implementation in Problem Solving & Felony Courts

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults

AIDANET Pediatrics

Drug Interaction Study Between Dolutegravir and Prednisone